Cite
HARVARD Citation
Merola, J. et al. (2023). Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 401 (10370), pp. 38-48. [Online].